Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses
After a conference lacking the wow factor, biotech winners and losers emerge.
One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
